

Zanamivir

Restricted antimicrobial Please contact Microbiology/ID/Antimicrobial pharmacist for further information																														
Form	Dectova® (Zanamivir) 10 mg/mL solution for infusion Each vial contains 200 mg of zanamivir (as hydrate) in 20 mL.																													
Reconstitution	Already in solution Dilute further before administration																													
Compatibility & Stability	Sodium chloride 0.9% ONLY																													
Administration	<p>IV Infusion</p> <ul style="list-style-type: none"> Remove an equivalent volume to the dose from a 100mL or 250mL sodium chloride 0.9% infusion bag and discard. Add the required dose to the remaining infusion bag. The final concentration must be 200 micrograms in 1mL or greater. The infusion bag should be gently manipulated by hand to ensure it is mixed thoroughly Give by intravenous infusion over 30 minutes. The recommended dose is 600 mg twice daily for 5 to 10 days given by intravenous infusion. <table border="1" style="margin: 10px auto;"> <thead> <tr> <th colspan="4" style="background-color: #0056b3; color: white;">Doses in Renal Impairment</th> </tr> <tr> <th style="background-color: #0056b3; color: white;">GFR (mL/min)</th> <th style="background-color: #0056b3; color: white;">Initial dose</th> <th style="background-color: #0056b3; color: white;">Maintenance dose</th> <th style="background-color: #0056b3; color: white;">Maintenance dose schedule</th> </tr> </thead> <tbody> <tr> <td>50 to <80</td> <td>600 mg</td> <td>400 mg twice daily</td> <td rowspan="2">Begin Maintenance dose 12 hours after initial dose</td> </tr> <tr> <td>30 to <50</td> <td>600 mg</td> <td>250 mg twice daily</td> </tr> <tr> <td>15 to < 30</td> <td>600 mg</td> <td>150 mg twice daily</td> <td>Begin Maintenance dose 24 hours after initial dose</td> </tr> <tr> <td>< 15</td> <td>600 mg</td> <td>60 mg (SIXTY) twice daily</td> <td>Begin Maintenance dose 48 hours after initial dose</td> </tr> </tbody> </table> <table border="1" style="margin: 10px auto; width: 100%;"> <thead> <tr> <th style="background-color: #0056b3; color: white;">CAPD/APD</th> <th style="background-color: #0056b3; color: white;">CVVHD</th> <th style="background-color: #0056b3; color: white;">HD</th> </tr> </thead> <tbody> <tr> <td style="background-color: #0056b3; color: white;">Dose as in GFR < 15mL/min</td> <td style="background-color: #0056b3; color: white;">Dose as in GFR 15-30 mL./min</td> <td style="background-color: #0056b3; color: white;">Dose as in FGR < 15mL/min</td> </tr> </tbody> </table>	Doses in Renal Impairment				GFR (mL/min)	Initial dose	Maintenance dose	Maintenance dose schedule	50 to <80	600 mg	400 mg twice daily	Begin Maintenance dose 12 hours after initial dose	30 to <50	600 mg	250 mg twice daily	15 to < 30	600 mg	150 mg twice daily	Begin Maintenance dose 24 hours after initial dose	< 15	600 mg	60 mg (SIXTY) twice daily	Begin Maintenance dose 48 hours after initial dose	CAPD/APD	CVVHD	HD	Dose as in GFR < 15mL/min	Dose as in GFR 15-30 mL./min	Dose as in FGR < 15mL/min
Doses in Renal Impairment																														
GFR (mL/min)	Initial dose	Maintenance dose	Maintenance dose schedule																											
50 to <80	600 mg	400 mg twice daily	Begin Maintenance dose 12 hours after initial dose																											
30 to <50	600 mg	250 mg twice daily																												
15 to < 30	600 mg	150 mg twice daily	Begin Maintenance dose 24 hours after initial dose																											
< 15	600 mg	60 mg (SIXTY) twice daily	Begin Maintenance dose 48 hours after initial dose																											
CAPD/APD	CVVHD	HD																												
Dose as in GFR < 15mL/min	Dose as in GFR 15-30 mL./min	Dose as in FGR < 15mL/min																												
Monitoring	Renal function should be monitored regularly during treatment. The patient should also be closely monitored for behavioural changes and any concerns discussed with a specialist. Acute reactions: <ul style="list-style-type: none"> abnormal behaviour, hallucinations, delirium convulsions, depressed level of consciousness diarrhoea oropharyngeal oedema and facial oedema, anaphylaxis rash, urticaria severe cutaneous adverse reactions (SCARs) 																													
Additional Information	<ul style="list-style-type: none"> Manufacturer advises reduce dose if creatinine clearance (GFR) less than 80 mL/minute (see table above) Can give undiluted over 30 minutes 																													

Information provided relates to Zanamivir (Dectova®) manufactured by GlaxoSmithKline.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542